4387723 method and apparatus for determining the level of neuromuscular block in a patient

2
1047 A method and apparatus for sealing a hole in the spinal canal of a patient made by a needle used to make a spinal tap. An elongated hemostatic thread is inserted into the lumen of the needle before the needle is removed from the patient after making a spinal tap and while the tip of the needle remains disposed in the hole in the spinal canal formed during penetration thereof by the needle. A wire inserted in the lumen of the needle is employed to advance the hemostatic member to the tip of the needle and to prevent withdrawal of the hemo- static member with the needle when the latter is subsequently withdrawn so that the hemostatic member will remain in situ in the hole as a plug to seal the same. 4389417 TREATMENT OF GRAY MATTER EDEMA Robert S. Bourke, Edward J. Cragoe, assigned to Merck & Co. Inc. The invention relates to the treatment of gray matter edema in the brain or spinal chord by the administration of (indanyloxy) acetic acids, and analogs and salts thereof. 4388467 CYCLOALKA (4,5) PYRROLO (2,3,-g) ISOQUINOLINES Leo Berger, Gary L. Olson, assigned to Hof- fmann-La Roche Inc. Neuroleptically active cycloalka (4,5) pyrrolo (2,3- g) isoquinolines of the formula. A wherein n, R 1, R2 and X are as hereinafter set forth, and inter- mediates therefore are described. 4388325 L-ARGININE D,L-PYRO- GLUTAMATE AS A PHARMACEUTICAL AGENT HAVING AN ACTIVITY AT THE NEURO-ENDOCRINAL LEVEL Giovann Orzalesi, Florence, Italy, assigned to Societa’ ltalo-Britannica L Manetti-H Roberts & C L-arginine D,L-pyroglutamate has a tonic activity at the neuro-endocrinal level with a specific effect in enhancing sexual behavior of Mammalia males, particularly in individuals of elderly age, humans being included. To be used in the pharmaceutical and veterinary field. 4388237 6(1-PIPERAZINYL), PIPERIDINO AND (l(HOMOPIPERAZINYL) ll- CYANOMETHYLENE MORPHANTHRIDINES Gerd Steiner, Albrecht Franke, Dieter Lenke, Hans-Juegen Teschendorf, Wolfgang Worstmann, Horst Kreiskott, Kirchheim, Federal Republic of Germany, assigned to BASF Aktiengesellschaft 6-Substituted 1 I-alkylene-morphanthridines, also referred to as 1 I-alkylene-dibenzo(b,e)-azepines, their pure cis- and trans-isomers, processes for their preparation, and therapeutic agents contain- ing these compounds, which may be used as drugs, in particular neuroleptics, sedatives, hyp- notics, analgesics, antidepressants or agents for treating Parkinson’s syndrome. 4387723 METHOD AND APPARATUS FOR DETERMINING THE LEVEL OF NEUROMUSCULAR BLOCK IN A PATIENT John Atlee, Maximillian Fiore, assigned to Wis- consin Alumni Research Foundation Electrical stimulus pulses are provided to the ulnar nerve of a patient and the adduction of the patient’s thumb in response to the pulses is mea- sured by a strain gage force transducer attached to the thumb and wrist of the patient. The force transducer provides an electrical output signal proportional to the magnitude of the thumb response, and this signal is subsequently ampli- fied, filtered, digitized and then provided to a con- troller which includes a microprocesser. In a pre- ferred procedure for determining the level of neu- romuscular block in a patient by estimating twitch height depression without using control responses, a train of four pulses is applied to the patient over a two second interval, and a magnitude of the response as measured by the transducer is received and stored by the microprocessor. The four re- sponse magnitude peaks are then individually compared to preselected threshold values, and the

Upload: vukien

Post on 30-Dec-2016

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 4387723 Method and apparatus for determining the level of neuromuscular block in a patient

1047

A method and apparatus for sealing a hole in the spinal canal of a patient made by a needle used to make a spinal tap. An elongated hemostatic thread is inserted into the lumen of the needle before the needle is removed from the patient after making a spinal tap and while the tip of the needle remains disposed in the hole in the spinal canal formed during penetration thereof by the needle. A wire inserted in the lumen of the needle is employed to advance the hemostatic member to the tip of the needle and to prevent withdrawal of the hemo- static member with the needle when the latter is subsequently withdrawn so that the hemostatic member will remain in situ in the hole as a plug to seal the same.

4389417

TREATMENT OF GRAY MATTER EDEMA

Robert S. Bourke, Edward J. Cragoe, assigned to Merck & Co. Inc.

The invention relates to the treatment of gray matter edema in the brain or spinal chord by the administration of (indanyloxy) acetic acids, and analogs and salts thereof.

4388467

CYCLOALKA (4,5) PYRROLO (2,3,-g) ISOQUINOLINES

Leo Berger, Gary L. Olson, assigned to Hof- fmann-La Roche Inc.

Neuroleptically active cycloalka (4,5) pyrrolo (2,3- g) isoquinolines of the formula. A wherein n, R 1, R2 and X are as hereinafter set forth, and inter- mediates therefore are described.

4388325

L-ARGININE D,L-PYRO- GLUTAMATE AS A

PHARMACEUTICAL AGENT HAVING AN ACTIVITY AT THE

NEURO-ENDOCRINAL LEVEL

Giovann Orzalesi, Florence, Italy, assigned to Societa’ ltalo-Britannica L Manetti-H Roberts & C

L-arginine D,L-pyroglutamate has a tonic activity at the neuro-endocrinal level with a specific effect in enhancing sexual behavior of Mammalia males, particularly in individuals of elderly age, humans being included. To be used in the pharmaceutical and veterinary field.

4388237

6(1-PIPERAZINYL), PIPERIDINO AND (l(HOMOPIPERAZINYL) ll-

CYANOMETHYLENE MORPHANTHRIDINES

Gerd Steiner, Albrecht Franke, Dieter Lenke, Hans-Juegen Teschendorf, Wolfgang Worstmann, Horst Kreiskott, Kirchheim, Federal Republic of Germany, assigned to BASF Aktiengesellschaft

6-Substituted 1 I-alkylene-morphanthridines, also referred to as 1 I-alkylene-dibenzo(b,e)-azepines, their pure cis- and trans-isomers, processes for their preparation, and therapeutic agents contain- ing these compounds, which may be used as drugs, in particular neuroleptics, sedatives, hyp- notics, analgesics, antidepressants or agents for treating Parkinson’s syndrome.

4387723

METHOD AND APPARATUS FOR DETERMINING THE

LEVEL OF NEUROMUSCULAR BLOCK IN A PATIENT

John Atlee, Maximillian Fiore, assigned to Wis- consin Alumni Research Foundation

Electrical stimulus pulses are provided to the ulnar nerve of a patient and the adduction of the patient’s thumb in response to the pulses is mea- sured by a strain gage force transducer attached to the thumb and wrist of the patient. The force transducer provides an electrical output signal proportional to the magnitude of the thumb response, and this signal is subsequently ampli- fied, filtered, digitized and then provided to a con- troller which includes a microprocesser. In a pre- ferred procedure for determining the level of neu- romuscular block in a patient by estimating twitch height depression without using control responses, a train of four pulses is applied to the patient over a two second interval, and a magnitude of the response as measured by the transducer is received and stored by the microprocessor. The four re- sponse magnitude peaks are then individually compared to preselected threshold values, and the

Page 2: 4387723 Method and apparatus for determining the level of neuromuscular block in a patient

degree twitch height depresslon estimated based on whether or not the response peaks are above or below the threshald levels, and indicia showing the degree of estimated twitch height depression is displayed to the operator.

4387151

THIAZOLXDINE DERIVATIVES AND THEIR USE

Yutaka Kawamatsu, Yujiro Yamamoto, Kyoto, Japan, assigned to Takeda Chemical Industries Ltd; Senju Pharmaceutical Co. Ltd.

A ~~~~o~~dine derivatives of the forrn~~a, wherein R is a phenyl group having 2 nuclear s&stituent groups selected from the group consisting of a lower alkyd having I to 6 carbon atoms, a lower afkoxy having I to 7 carbon atoms, hydroxyt and a carboxylic acyloxy having I to 4 carbon atoms, or a phenyl group having a methylene&oxy group in adjacent positions on its ring; Rl is H or an alkyd having 1 to 5 carbon atoms, or a physidogi- tally acceptable saft thereof is a novel compound

havmg the activity to control certain chronic symptoms due to diabetes, such as diabetic cata- ract. diabetic neuropathy and diabetic retinosis.

4386603

DLSTRACTIQN DEVICE FOR SPH’NAL DISTRACTION SYSTEMS

Jack Mayfieid

A distractor device is used to apply force to a pair of distraction hooks each positioned between selected pairs of vertebrae. The hooks are eompo- nents of a spinal distraction system used in the treatment of spinal deformities or fractures. The distractor device ineIudes a threaded rod having a pair of force applying members shiftably mounted on the rod and each engaging one of the distrac- tion hooks. A threaded nut on the rod engages and causes one of the force applying members to be moved away from the other force applying member to exert a distraction force on the distrac- tion hooks. Each force applying member is pivot- ally mounted on the rod and is also comprised of a pair of pivotally connected elements whereby the pivoting movement between the force apply- ing members and the rod permits positioning and adjustment of the distractor device in confined spaces.

For in~orrnat~o~ about ~A~~AR~~* and VIDEO PATSEARCH@:

Pergamon International Pergamon InfoLine Pergamon Press Information Corporation Limited Canada Ltd

1340 Old Chain Bridge Road 12 Vandy Street 150 Consumes Road%&? 104 McLean, Virginia 22101 London EC2A 2DE Willowdak, Ontario USA England CanadaM2J lP9 Telephone (703) 442-@&N Telephone: (01) 377 4650 Te!+zphone: (4%) 497-8337 Telex:90-18% I Telex: 88114614 TeIex: 065-25450

Patent Section Editors:

Pergamon Press, inc. Pergamon Press Ltd.

Maxwefl House Headington Hifl Hall Fairview Park Oxford OX3 03W Elmsford, New York 10523 England